Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146536 · ClinicalTrials.gov registry record
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 78
- Enrollment target
NCT00146536 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 78 participants.
The verdict
NCT00146536 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
Study Summary
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2004-11 |
| Est. Completion | 2012-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146536
The ClinicalTrials.gov registry entry for NCT00146536 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00146536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146536 about?
NCT00146536 is a clinical study titled "Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy". The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.
What is the current status of trial NCT00146536?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2004-11. Estimated completion is 2012-11.
Who is sponsoring clinical trial NCT00146536?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.